Zelebrudomide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zelebrudomide" in English language version.

Last modified: 09:51:18, 3 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

5^th place

2^nd place

doi.org (Global: 2^nd place; English: 2^nd place)

Salvaris RT, Brennan J, Lewis KL (February 2025). "BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL". Cancers. 17 (3): 557. doi:10.3390/cancers17030557. PMC 11817010. PMID 39941922.
Robbins DW, Noviski MA, Tan YS, Konst ZA, Kelly A, Auger P, et al. (February 2024). "Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies". Journal of Medicinal Chemistry. 67 (4): 2321–2336. doi:10.1021/acs.jmedchem.3c01007. PMID 38300987.

Salvaris RT, Brennan J, Lewis KL (February 2025). "BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL". Cancers. 17 (3): 557. doi:10.3390/cancers17030557. PMC 11817010. PMID 39941922.
Robbins DW, Noviski MA, Tan YS, Konst ZA, Kelly A, Auger P, et al. (February 2024). "Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies". Journal of Medicinal Chemistry. 67 (4): 2321–2336. doi:10.1021/acs.jmedchem.3c01007. PMID 38300987.